Accéder au contenu
Merck
Toutes les photos(2)

Documents

93813

Supelco

Cyclophosphamide monohydrate

analytical standard

Synonyme(s) :

2-[Bis(2-chloroethyl)amino]tetrahydro-2H-1,3,2-oxazaphosphorine 2-oxide, Cytoxan

Se connecterpour consulter vos tarifs contractuels et ceux de votre entreprise/organisme
Toutes les photos(2)

About This Item

Formule empirique (notation de Hill):
C7H15Cl2N2O2P · H2O
Numéro CAS:
6055-19-2
Poids moléculaire :
279.10
Numéro Beilstein :
4678992
Numéro CE :
200-015-4
Numéro MDL:
MFCD00149395
Code UNSPSC :
41116107
ID de substance PubChem :
329770272
Nomenclature NACRES :
NA.24

Qualité

analytical standard

Niveau de qualité

100

Pureté

≥98.0% (HPLC)

Durée de conservation

limited shelf life, expiry date on the label

Technique(s)

HPLC: suitable
gas chromatography (GC): suitable

Impuretés

6.45% water (theory, monohydrate)

Pf

47-52 °C
49-51 °C (lit.)

Application(s)

forensics and toxicology
veterinary

Format

neat

Température de stockage

2-8°C

Chaîne SMILES 

[H]O[H].ClCCN(CCCl)P1(=O)NCCCO1

InChI

1S/C7H15Cl2N2O2P.H2O/c8-2-5-11(6-3-9)14(12)10-4-1-7-13-14;/h1-7H2,(H,10,12);1H2

Clé InChI

PWOQRKCAHTVFLB-UHFFFAOYSA-N

Vous recherchez des produits similaires ? Visite Guide de comparaison des produits

Application

Refer to the product′s Certificate of Analysis for more information on a suitable instrument technique. Contact Technical Service for further support.

Actions biochimiques/physiologiques

Cyclophosphamide is a cytotoxic nitrogen mustard derivative widely used in cancer chemotherapy. It cross-links DNA, causes strand breakage, and induces mutations. Its clinical activity is associated with a decrease in aldehyde dehydrogenase 1 (ALDH1) activity.

Pictogrammes

Skull and crossbonesHealth hazard
GHS06,GHS08

Mention d'avertissement

Danger

Mentions de danger

H301,H340,H350,H360FD

Classification des risques

Acute Tox. 3 Oral - Carc. 1B - Muta. 1B - Repr. 1A

Code de la classe de stockage

6.1C - Combustible acute toxic Cat.3 / toxic compounds or compounds which causing chronic effects

Classe de danger pour l'eau (WGK)

WGK 3

Choose from one of the most recent versions:

Certificats d'analyse (COA)

Lot/Batch Number
BCCJ5425
BCCG4445
BCCB7788
BCBT1588
BCBM8984V

Don't see the Right Version?

If you require a particular version, you can look up a specific certificate by the Lot or Batch number.

Search for a COA

Déjà en possession de ce produit ?

Retrouvez la documentation relative aux produits que vous avez récemment achetés dans la Bibliothèque de documents.

Consulter la Bibliothèque de documents

Ji-Young Lee et al.
Chemosphere, 268, 128817-128817 (2020-11-10)
Cyclophosphamide (CP) is a widely used anticancer drug and an immunosuppressant. Since CP is nonbiodegradable, it is hardly removed by the conventional wastewater treatment processes, resulting in continuous detection in surface water. In this study, the degradation of CP during
Feng Zhao et al.
Pharmaceutical biology, 52(7), 797-803 (2014-01-08)
The in vitro and in vivo antitumor activities of ardisiphenol D, a natural product isolated from the roots of Ardisa brevicaulis Diels (Myrsinaceae), have been studied. Previously, we have isolated and identified some chemical constituents from this plant. Furthermore, these
Masahiro Murakami-Nakayama et al.
Journal of pharmacological sciences, 127(2), 223-228 (2015-03-03)
Cav3.2 T-type Ca(2+) channels targeted by H2S, a gasotransmitter, participate in cyclophosphamide-induced cystitis and bladder pain. Given that zinc selectively inhibits Cav3.2 among T-channel isoforms and also exhibits antioxidant activity, we examined whether polaprezinc (zinc-l-carnosine), a medicine for peptic ulcer
Yue Jia et al.
Apoptosis : an international journal on programmed cell death, 20(4), 551-561 (2015-02-11)
Human (HN) prevents stress-induced apoptosis in many cells/tissues. In this study we showed that HN ameliorated chemotherapy [cyclophosphamide (CP) and Doxorubicin (DOX)]-induced male germ cell apoptosis both ex vivo in seminiferous tubule cultures and in vivo in the testis. HN
Lamprini Skriapa et al.
Journal of neuroimmunology, 276(1-2), 150-158 (2014-09-30)
Antibodies against MuSK seem to be the pathogenic factor in approximately 5-8% of myasthenia gravis (MG) patients. We aim to develop an antigen-specific therapy in which only MuSK antibodies will be removed from patients' plasma using MuSK extracellular domain (MuSK-ECD)
Afficher tous les articles scientifiques apparentés

Notre équipe de scientifiques dispose d'une expérience dans tous les secteurs de la recherche, notamment en sciences de la vie, science des matériaux, synthèse chimique, chromatographie, analyse et dans de nombreux autres domaines..

Contacter notre Service technique